Trials / Recruiting
RecruitingNCT06543914
Observational Study of Oral Atogepant to Evaluate Real-World Effectiveness in Adult Participants With Migraine
A ProspeCtive ObseRvatioNal Study of Atogepant Effectiveness in Routine Clinical Practice
- Status
- Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 1,000 (estimated)
- Sponsor
- AbbVie · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Migraine is a neurological disease characterized by moderate or severe headache, associated with nausea, vomiting, and/or sensitivity to light and sound. This study will evaluate the effectiveness of atogepant in treating adult participants with migraine in a real-world setting. Atogepant is an approved drug for preventive treatment of migraine in adults. Approximately 1000 adult participants who are prescribed atogepant by their doctors will be enrolled in this study across the world. Participants will receive atogepant oral tablets as prescribed per standard clinical practice and will be followed for 2 years. There is expected to be no additional burden for participants in this trial. Participants will attend regular visits during the study at a hospital or clinic according to their routine clinical practice.
Conditions
Timeline
- Start date
- 2024-11-26
- Primary completion
- 2029-02-01
- Completion
- 2029-02-01
- First posted
- 2024-08-09
- Last updated
- 2026-02-13
Locations
111 sites across 14 countries: United States, Belgium, Canada, Germany, Italy, Netherlands, Norway, Portugal, Spain, Sweden, Switzerland, Taiwan, United Arab Emirates, United Kingdom
Source: ClinicalTrials.gov record NCT06543914. Inclusion in this directory is not an endorsement.